Oxford Nanopore Technologies PLC
Company Profile
Business description
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
Contact
Edmund Halley Road
Gosling Building, Oxford Science Park
OxfordOxfordshireOX4 4DQ
GBRT: +44 8450347900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,315
Stocks News & Analysis
stocks
Moated ASX share crashes amid weak trading update
stocks
A collection of our best stock opportunities
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,023.30 | 56.60 | 0.63% |
CAC 40 | 7,857.36 | 56.48 | 0.72% |
DAX 40 | 24,217.37 | 247.01 | 1.03% |
Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
FTSE 100 | 9,136.32 | 54.88 | 0.60% |
HKSE | 25,473.40 | 51.05 | -0.20% |
NASDAQ | 21,098.29 | 80.29 | -0.38% |
Nikkei 225 | 40,682.14 | 7.59 | 0.02% |
NZX 50 Index | 12,961.28 | 24.87 | 0.19% |
S&P 500 | 6,370.86 | 18.91 | -0.30% |
S&P/ASX 200 | 8,764.10 | 59.50 | 0.68% |
SSE Composite Index | 3,632.41 | 22.70 | 0.63% |